☰

Alden Klarer, Ph.D.

Affiliations: 
2013 University of Louisville, Louisville, KY, United States 
Area:
Biochemistry, Molecular Biology
Google:
"Alden Klarer"
Mean distance: (not calculated yet)
 
Tree Publications Similar researchers PubMed Report error

Parents

Sign in to add mentor
Sucheta Telang grad student 2013 University of Louisville
 (6-Phosphofructo-2-kinase inhibition induces autophagy as a survival mechanism.)

Children

Sign in to add trainee

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Clem BF, O'Neal J, Klarer AC, et al. (2016) Clinical development of cancer therapeutics that target metabolism. Qjm : Monthly Journal of the Association of Physicians. 109: 367-72
Chesney J, Clark J, Klarer AC, et al. (2014) Fructose-2,6-bisphosphate synthesis by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growth. Oncotarget. 5: 6670-86
Yalcin A, Clem BF, Imbert-Fernandez Y, et al. (2014) 6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27. Cell Death & Disease. 5: e1337
Klarer AC, O'Neal J, Imbert-Fernandez Y, et al. (2014) Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism. Cancer & Metabolism. 2: 2
Clem BF, O'Neal J, Tapolsky G, et al. (2013) Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer. Molecular Cancer Therapeutics. 12: 1461-70
Telang S, Nelson KK, Siow DL, et al. (2012) Cytochrome c oxidase is activated by the oncoprotein Ras and is required for A549 lung adenocarcinoma growth. Molecular Cancer. 11: 60
Telang S, Clem BF, Klarer AC, et al. (2012) Small molecule inhibition of 6-phosphofructo-2-kinase suppresses t cell activation. Journal of Translational Medicine. 10: 95
Chesney J, Rasku MA, Klarer AC, et al. (2011) Effect of denileukin diftitox on serum GM-CSF and clinical responses in stage IV melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2507
Telang S, Rasku MA, Clem AL, et al. (2011) Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma. Bmc Cancer. 11: 515
See more...